Legal Representation
Attorney
Donna J. Bunton
USPTO Deadlines
Application History
29 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 3, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jan 3, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jun 5, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 3, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jun 3, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jun 3, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 2, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 30, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 30, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 30, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jun 5, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jun 3, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jun 3, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jun 3, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Dec 3, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Oct 9, 2019 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Oct 8, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Oct 8, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 18, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Sep 5, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Aug 29, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 29, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Aug 29, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 29, 2019 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Aug 29, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Aug 28, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 22, 2019 | MDSC | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Jun 21, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 11, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS
Class 042
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS
First Use Anywhere:
Jun 5, 1995
First Use in Commerce:
Jun 5, 1995
Additional Information
Design Mark
The mark consists of the letters "hb" in lower case letters with the letter "h" at the top and the letter "b" on the bottom sharing the end of the letter "h" slant to form the "b" inside of a slanted shaded square.
Color Claim
Color is not claimed as a feature of the mark.
Classification
International Classes
005
042